16 results about "Retinal function" patented technology

The present application provides a method for diagnosing and / or evaluating the presence or absence, severity or degree of the improvement of a retinal disease in a subject, which comprises determining and / or evaluating circulatory parameters, retinal function, retina morphology and / or visual relating quality of life (QOL).

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing symmetric or asymmetric optic with aspheric surface which redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The intraocular lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the intraocular lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the intraocular lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

A system for testing different regions of the retina of a subject for retinal function, said system comprising: a monitor configured to display a visual electrophysiology stimulus to the subject, wherein the visual electrophysiology stimulus comprises a four ring visual electrophysiology stimulus; at least one active electrode; at least one reference electrode; and a computer configured to receive electrical signals from said at least one active electrode and said at least one reference electrode, and process the electrical signals.

This invention belongs to the field of biopharmaceuticals and relates to a gene therapy drug for hereditary retinal dystrophy related to RLBP1 gene mutations and its application. Specifically, it involves constructing a recombinant AAV-RLBP1 gene therapy drug, which is then injected intravitreally to infect retinal pigment epithelial cells and Müller cells, causing them to express complete and active RLBP1 protein. This invention utilizes a modified AAV vector to package codon-optimized human RLBP1-cDNA, enabling the expression of complete and active RLBP1 protein, which participates in the visual circulation pathway, rescuing retinal dysfunction caused by pathogenic mutations in the RLBP1 gene, improving visual function in patients, or delaying disease progression.

The invention relates to application of vorinostat in preparation of a medicine for treating retina photoreceptor cell degenerative diseases, and aims to solve the technical problem that an effective treatment medicine and an effective treatment method for hereditary retina photoreceptor cell degenerative diseases are lacked. On the basis of a typicality animal model, the whole process of retina photoreceptor cell degeneration is defined, and it is confirmed that in the retina photoreceptor cell degeneration process, the histone H3K27ac level is remarkably changed, the activity of histone acetyltransferase CBP / p300 is improved, and the expression of histone deacetylase HDAC6 is improved; based on the molecular mechanism of histone acetylation modification in the retina photoreceptor cell degenerative change process, the precise treatment medicine and scheme are designed and explored: the expression of histone deacetylase HDAC6 is specifically inhibited by SAHA, the H3K27ac acetylation level is improved, the expression of an Hdc gene is promoted, the expression of Hdc is increased, and the effect of treating the retina photoreceptor cell degenerative change is achieved. The retina function of retina photoreceptor cell degenerative lesion is partially recovered.

This invention discloses an extracellular vesicle derived from Gastrodia elata, its preparation method, and its use in preparing drugs for treating glaucoma, belonging to the field of biomedical technology. This invention claims protection for an extracellular vesicle prepared from dried Gastrodia elata. The extracellular vesicles provided by this invention have no significant cytotoxicity and good biocompatibility. Studies have shown that these extracellular vesicles can significantly inhibit apoptosis of R28 cells and loss of Brn3a⁺ cells in the mouse retina in a glutamate excitotoxicity model. In a glaucoma model, these extracellular vesicles can effectively protect the survival of retinal ganglion cells (RGCs) and retinal function, and can significantly reduce retinal neuroinflammatory responses in the glaucoma model. Therefore, the extracellular vesicles provided by this invention have a clear anti-glaucoma-related retinal damage effect and possess great potential for development into drugs for treating glaucoma.

The invention discloses an application of CD8 alpha positive macrophages in treatment of optic nerve injury. In the application, optic nerve injury treatment is specifically shown as follows: the survival of retinal ganglion cells after minor optic nerve injury is promoted; improving visual function recovery after optic nerve injury of the mouse, wherein the visual function recovery comprises retina ganglion cell function, retina function and vision recovery; the product is a medicine or a test reagent. Research shows that the survival rate of retina ganglion cells (RGCs) can be improved through CD8 alpha positive macrophage treatment, meanwhile, visual behavioral detection verifies that the CD8 alpha positive macrophage has a certain effect on long-term vision improvement of mice, and compared with an existing treatment method, the CD8 alpha positive macrophage is better in effect and has important clinical value, and the CD8 alpha positive macrophage has a good application prospect. And a new thought is provided for optic nerve injury treatment, so that the method has a good practical application value.

The application relates to a retinal cell type-based visual function related parameter acquisition system and belongs to the technical field of medical auxiliary systems. The application aims to accurately acquire a retinal cell type-based visual function related parameter acquisition system of L cone, M cone, S cone, ipRGCs and other different retinal cell type function related physiological parameters. The system of the application comprises a stimulation presentation module, a brightness calibration module, a biological signal acquisition module, a multi-dimensional parameter extraction and cell type specific parameter decoupling module, a parameter analysis and standardized output module, a user interaction module and a data storage module. The application can provide a portable, objective, non-invasive and cell type specific retinal function related parameter acquisition technology, provide comprehensive and reliable technical support for visual function evaluation, is suitable for large-scale parameter acquisition and home monitoring, and solves many limitations of the prior art.

The invention belongs to the technical field of medicinal preparations with natural components, and particularly relates to application of a semen cuscutae aqueous extract and / or active components thereof in preventing or relieving asthenopia and protecting the retina function. The invention provides an application of a semen cuscutae aqueous extract and / or an active component thereof in preparation of one or more of the following products: (1) a product for preventing asthenopia; (2) a product for relieving asthenopia; (3) a product for protecting the retina; the active component of the semen cuscutae aqueous extract is obtained by separating and purifying the semen cuscutae aqueous extract through macroporous adsorption resin; an eluent for separation and purification is water. The invention provides the application of the semen cuscutae aqueous extract and / or the active components thereof in preventing or relieving asthenopia and protecting the retina function, provides a natural plant active raw material with a definite effect for developing a novel eye health product, and has an important application value in the fields of medicines and health products.

The present invention relates to a vision protection functional food and its production process, which specifically comprises the following steps: (1) preparing fucoxanthin nanoparticles by alkaline electrolyzed water-ultrasonic coupling technology; (2) mixing the fucoxanthin nanoparticle powder with quercetin, β-sitosterol, docosahexaenoic acid, water or solid filler excipients in proportion to obtain an aqueous solution mixture or a solid mixture; (3) homogenizing and filtering the aqueous solution mixture; or sieving the solid mixture; (4) sterilizing and filling the filtered aqueous solution mixture, or tableting and granulating the sieved solid mixture, and preparing the mixture into products respectively. The present invention can significantly improve the antioxidant capacity of the eyes and retinal function, effectively prevent myopia and reduce the risk of retinal-related ophthalmic diseases; the product can be made into capsules, tablets, granules, oral liquids or beverages, has a simple production process, is low in cost, and is suitable for large-scale industrial production.

Methods and compositions for treating uveitis are provided. The methods include administering to a subject a single-domain antibody (sdAb) comprising the amino acid sequence set forth in SEQ ID NO:1. In certain embodiments, the sdAb is administered systemically at a therapeutically effective dose and inhibits STAT3 activation in CD4+ T-cells, thereby reducing Th17-mediated inflammation. The methods may be used to treat autoimmune uveitis and may improve retinal function as measured by electroretinogram (ERG) amplitude. Also provided are pharmaceutical compositions comprising the sdAb and a pharmaceutically acceptable carrier. Further methods of modulating immune responses associated with uveitis are disclosed, including reducing cytokine production and T-cell-mediated inflammation.

The invention relates to a visual cortical nerve regulation and control method based on theta explosive type transcranial magnetic stimulation, the method adopts a magnetic resonance guided MNI coordinate system to position an occipital pole stimulation area, the visual cortical layer is a primary visual cortical layer, the theta explosive type refers to a theta explosive type stimulation mode, and the theta explosive type refers to a theta explosive type transcranial magnetic stimulation mode. The TMS breaks through the limitation that a traditional therapy focuses on retina local repair, cortex-retina function compensation is achieved by regulating visual cortex nerve plasticity, clinical data shows that BCVA of an MMD patient can be averagely improved by 0.22 log MAR, the macular sensitivity is remarkably improved, the treatment effect on extreme myopia patients with the axial length larger than or equal to 32 mm is better, and the application prospect is wide. The treatment blank that the existing invasive therapy is taboo due to the fragile eyeball structure is filled. The non-invasive operation avoids the risk of operative complications, no adverse reaction report exists in the treatment process, the tolerance of a patient is good, the curative effect is kept stable in follow-up visit of four weeks, and repeated invasive operation is not needed.

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing a piggyback lens which in combination with the cornea and an existing lens in the patient's eye redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The piggyback lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the piggyback lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the piggyback lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.

The invention discloses a gene therapy method for treating retina degenerative diseases by targeting USP8 and application of the gene therapy method. The research finds that the USP8 expression in an aging and retinal degeneration mouse model is down-regulated; the mouse with Usp8 knockout has retinal degeneration, and the retinal degeneration can be rescued through USP8 overexpression. The discovery shows that the USP8 plays a key role in maintaining the steady state of retinal cells and delaying the retinal degeneration process. By regulating and controlling the expression level of the USP8, the retina function can be remarkably improved, and a new potential target and strategy are provided for treatment of retinal degenerative diseases.

The application discloses a flexible near-infrared artificial retina device and a preparation method thereof. The flexible near-infrared artificial retina device comprises a flexible substrate, a bottom electrode formed on the flexible substrate, a functional layer comprising an organic ferroelectric polymer film, a rare earth up-conversion nanomaterial and an organic ferroelectric polymer film laminated structure formed on the bottom electrode, and a top transparent electrode formed on the functional layer. The device is excited by near-infrared light, the near-infrared light signal is converted into a reproducible visible light signal by using the anti-Stokes luminescence capability of the rare earth up-conversion nanomaterial, the collection and signal reproduction functions of the near-infrared waveband light information are completed, the processing and memory of the near-infrared information are realized by using the continuously adjustable non-volatile resistance state, and finally the simulation of the artificial retina function is realized.

Systems and methods are provided for improving overall vision in patients suffering from a loss of vision in a portion of the retina (e.g., loss of central vision) by providing symmetric or asymmetric optic with aspheric surface which redirects and / or focuses light incident on the eye at oblique angles onto a peripheral retinal location. The intraocular lens can include a redirection element (e.g., a prism, a diffractive element, or an optical component with a decentered GRIN profile) configured to direct incident light along a deflected optical axis and to focus an image at a location on the peripheral retina. Optical properties of the intraocular lens can be configured to improve or reduce peripheral errors at the location on the peripheral retina. One or more surfaces of the intraocular lens can be a toric surface, a higher order aspheric surface, an aspheric Zernike surface or a Biconic Zernike surface to reduce optical errors in an image produced at a peripheral retinal location by light incident at oblique angles.